Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−105.58 EUR
−12.74 M EUR
0.00 EUR
10.88 M
About Hepion Pharmaceuticals, Inc.
Sector
Industry
CEO
John Patrick Brancaccio
Website
Headquarters
Morristown
Founded
2013
FIGI
BBG0088F4764
Hepion Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of drug therapy for treatment of chronic liver diseases. It focuses on the development of its product candidate, Rencofilstat, a cyclophilin inhibitor that targets biochemical pathways involved in the progression of liver disease. The company was founded on May 15, 2013 and is headquartered in Morristown, NJ.
Hepion Pharmaceuticals - an opportunity like no other* cautious investment opportunity - low market capital *
4-years of price action resistance, a 99.96% correction, and now a higher low in price action following the oversold condition (orange column). So many reasons to be bullish on this stock. Let’s go through them.
1) As mentioned above, price
Get Long !!There's a lot of selling pressure/resistance here at this 2.31 - 2.33 price. Once this is all bought, I am expecting a significant move to the upside. I am long the stock and the April 16 $2.50 calls. Good luck to all, and I welcome all constructive comments. I will up-date this tomorrow.
Break-out potential for HEPAUsing lines to trace price movement from MAY '19 you can draw the lines to a point at its current price where its sitting on a plateau that has proven to be a strong support through-out the assets time-span. There is potential for it to carry on at this plateau for another 24 hours or so but due to
HEPA TargetsUsing the golden ratio as a price target, and previous magnitudes, HEPA looks primed for a run up to the $8.95-$9.93 range by EOY. The top line of the broadening formation will likely cause resistance and a chance for a nice pullback opportunity. The volume of this stock has dried up as the short vo
HEPARetested the resistance area as I said last Friday. Tough area to get through. I do expect it to go through at some point. Hopefully sooner rather than later!
HEPAAt support. Good dip buy for the homies to hop in before another retest to the 2.31 support level
HEPACalled the bottom of the chart back on April 15th. White lines are my near-term price targets for $HEPA. Still think it'll reach $2.52 for a swing trade of 70% gains!
See all ideas
Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Related stocks
Frequently Asked Questions
The current price of 3360 is 0.33 EUR — it has increased by 1.12% in the past 24 hours. Watch HEPION PHARMACEUTICALS INC stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on GETTEX exchange HEPION PHARMACEUTICALS INC stocks are traded under the ticker 3360.
3360 stock has risen by 54.24% compared to the previous week, the month change is a −4.48% fall, over the last year HEPION PHARMACEUTICALS INC has showed a −52.60% decrease.
3360 reached its all-time high on Mar 20, 2025 with the price of 0.78 EUR, and its all-time low was 0.20 EUR and was reached on Apr 23, 2025. View more price dynamics on 3360 chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
3360 stock is 8.26% volatile and has beta coefficient of 1.56. Track HEPION PHARMACEUTICALS INC stock price on the chart and check out the list of the most volatile stocks — is HEPION PHARMACEUTICALS INC there?
Yes, you can track HEPION PHARMACEUTICALS INC financials in yearly and quarterly reports right on TradingView.
HEPION PHARMACEUTICALS INC is going to release the next earnings report on May 13, 2025. Keep track of upcoming events with our Earnings Calendar.
3360 net income for the last quarter is −1.49 M EUR, while the quarter before that showed −4.37 M EUR of net income which accounts for 65.80% change. Track more HEPION PHARMACEUTICALS INC financial stats to get the full picture.
No, 3360 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, 3360 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade HEPION PHARMACEUTICALS INC stock right from TradingView charts — choose your broker and connect to your account.